Cargando…

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer (mCRC). However, only a small percentage of mCRC patients are sensitive to anti-EGFR therapy and even the best cases finall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ben, Wang, Lu, Qiu, Hong, Zhang, Mingsheng, Sun, Li, Peng, Ping, Yu, Qianqian, Yuan, Xianglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354808/ https://www.ncbi.nlm.nih.gov/pubmed/28002810 http://dx.doi.org/10.18632/oncotarget.14012

Ejemplares similares

Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis
por: Wang, Lu, et al.
Publicado: (2016)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer
por: Chu, Jinjin, et al.
Publicado: (2022)

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
por: Zhou, Jing, et al.
Publicado: (2021)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
por: Kasper, Stefan, et al.
Publicado: (2017)

Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer
por: Qiu, Tianzhu, et al.
Publicado: (2018)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Prophylactical Low Dose Whole-Liver Irradiation Inhibited Colorectal Liver Metastasis by Regulating Hepatic Niche in Mice
por: Wang, Lu, et al.
Publicado: (2020)

Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer
por: Huang, Changhao, et al.
Publicado: (2020)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
por: Parseghian, Christine, et al.
Publicado: (2023)

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
por: Vangala, Deepak, et al.
Publicado: (2021)

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy
por: Wei, Shanshan, et al.
Publicado: (2022)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response
por: Li, Zhe-Zhen, et al.
Publicado: (2016)

Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer
por: Woolston, Andrew, et al.
Publicado: (2021)

Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
por: Graves-Deal, Ramona, et al.
Publicado: (2019)

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
por: Woolston, Andrew, et al.
Publicado: (2019)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Heterogeneous EGFR Gene Copy Number Increase Is Common in Colorectal Cancer and Defines Response to Anti-EGFR Therapy
por: Ålgars, Annika, et al.
Publicado: (2014)

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
por: Gelfo, Valerio, et al.
Publicado: (2016)

Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion
por: Acencio, Milena Marques Pagliarelli, et al.
Publicado: (2017)

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
por: Ying, Hou-Qun, et al.
Publicado: (2015)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy
por: Yang, Wentao, et al.
Publicado: (2022)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Update on Anti-EGFR Therapy
por: Chua, Daniel, et al.
Publicado: (2009)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal Cancer
por: Knebel, Franciele H., et al.
Publicado: (2019)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
por: Luo, Maochao, et al.
Publicado: (2021)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Research progress on criteria for discontinuation of EGFR inhibitor therapy
por: Zhuang, Hong-qing, et al.
Publicado: (2012)

Immune Resistance and EGFR Antagonists in Colorectal Cancer
por: Giordano, Guido, et al.
Publicado: (2019)

Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer
por: Flynn, John F., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mk73lh4vq4fli708glhtrcgk1o